Fig. 1: Flow chart of patient selection. | Blood Cancer Journal

Fig. 1: Flow chart of patient selection.

From: Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma

Fig. 1

*Among the 3162 patients that were excluded because they did not receive 6x R-CHOP21 nor 6x R-CHOP21 + 2 R, 657 patients did not receive therapy, 1159 patients received 8x R-CHOP21, and 1346 received other types of therapy (Supplemental Table 1 provides more information on the characteristics of these patients). DLBCL, diffuse large B-cell lymphoma; NCR, Netherlands Cancer Registry; EBV Epstein-Barr Virus; 6x R-CHOP21, 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 21 days; 6x R-CHOP21 + 2 R, 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 21 days and two subsequent cycles of rituximab.

Back to article page